Supplementary Figure S4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Tumor fraction changes significantly predict long-term clinical benefit from immune checkpoint inhibitors, emphasizing their relevance in treatment planning.
• The analysis identified critical thresholds for tumor fraction change, providing specific metrics for assessing patient outcomes with this intervention.
• Using a forest plot analysis, the study examined real-world data across various cancer types, highlighting the importance of ctDNA monitoring in clinical settings.
• Findings support the potential for personalized therapy approaches in immuno-oncology, indicating further research is necessary to validate these observations.

Abstract